Rare Cancer News & Clinical Trials » Google - Merkel Cell Cancer

Feeds

4628 items (4628 unread) in 80 feeds

• Google - Acinar Cell Carcinoma (5 unread)
• PubMed - Acinar Cell Carcinoma (24 unread)
• Trial - Acinar Cell Carcinoma

• Google - Acinic Cell Carcinoma (5 unread)
• PubMed - Acinic Cell Carcinoma (28 unread)
• Trial - Acinic Cell Carcinoma

• Google - Adenoid Cystic Carcinoma (15 unread)
• PubMed - Adenoid Cystic Carcinoma (37 unread)
• Trial - Adenoid Cystic Carcinoma (5 unread)

• Google - Adrenal Cancer (90 unread)
• Google - Adrenocortical Carcinoma (16 unread)
• PubMed - Adrenal Cancer (183 unread)
• PubMed - Adrenocortical Carcinoma (35 unread)
• Trial - Adrenal Cancer (10 unread)
• Trial - Adrenocortical Carcinoma (1 unread)

• Google - Ampullary Cancer (1 unread)
• PubMed - Ampullary Cancer (13 unread)
• Trial - Ampullary Carcinoma

• Google - Anal Cancer (150 unread)
• PubMed - Anal Cancer (93 unread)
• Trial - Anal Cancers (9 unread)

• Google - Angiosarcoma (20 unread)
• PubMed - Angiosarcoma (51 unread)
• Trial - Angiosarcoma (2 unread)

• Google - Appendix Cancer (7 unread)
• PubMed - Appendix Cancer (21 unread)
• Trial - Appendix Cancer (7 unread)

• Google - Bile Duct Cancer (76 unread)
• Google - Cholangiocarcinoma (29 unread)
• PubMed - Bile Duct Cancer (160 unread)
• PubMed - Cholangiocarcinoma (102 unread)
• Trial - Bile Duct Cancer (6 unread)
• Trial - Cholangiocarcinoma (13 unread)

• Google - Rare Brain Tumor (558 unread)
• Google - Rare CNS Tumor (1 unread)
• PubMed - Ganglioglioma (7 unread)
• PubMed - Rare Brain Tumor (108 unread)
• PubMed - Rare CNS Tumor (125 unread)
• Trial - Brain Tumor (143 unread)
• Trial - CNS Tumor (209 unread)
• Trial - Ganglioglioma

• Google - Carcinoid (56 unread)
• PubMed - Carcinoid (81 unread)
• Trials - Carcinoid (6 unread)

• Google - Merkel Cell Cancer (39 unread)
• Google - Neuroendocrine Tumor (48 unread)
• PubMed - Merkel Cell Cancer (26 unread)
• PubMed - Neuroendocrine Tumor (103 unread)
• Trial - Merkel Cell Cancer
• Trial - Neuroendocrine Cancers (75 unread)

• Google - Gall Bladder Cancer (156 unread)
• PubMed - Gall Bladder Cancer (71 unread)
• Trials - Gall Bladder Cancer

• Google - Hemangioendothelioma
• PubMed - Hemangioendothelioma (23 unread)
• Trial - Hemangioendothelioma

• Google - Hepatoblastoma (10 unread)
• PubMed - Hepatoblastoma (21 unread)
• Trial - Hepatoblastoma

• Google - Insulinoma (4 unread)
• PubMed - Insulinoma (40 unread)
• Trial - Insulinoma (1 unread)

• Google - Phyllodes Tumor (2 unread)
• PubMed - Phyllodes Tumor (19 unread)
• Trial - Phyllodes

• Google - Pseudomyxoma Peritonei (6 unread)
• PubMed - Pseudomyxoma Peritonei (PMP) (13 unread)
• Trial - Pseudomyxoma Peritonei

• Google - Rhabdomyosarcoma (107 unread)
• PubMed - Rhabdomyosarcoma (72 unread)
• Trial - Rhabdomyosarcoma (12 unread)

• Google - Sarcoma (172 unread)
• PubMed - Sarcoma (362 unread)
• Trial - Sarcoma (68 unread)

• Twitter / Bruce_S (229 unread)
• Twitter / childrenscancer (245 unread)
• Twitter / LiftUpEllie (15 unread)
• Twitter / LivingBeyond (55 unread)
• Twitter / MDAndersonNews (126 unread)
• Twitter / vaginal_cancer

Google - Merkel Cell Cancer (39 unread)

• 

  PET more sensitive than CT for Merkel cell carcinoma - Oncology Nurse Advisor

  Posted: May 16th, 2012, 6:59am MDT

  PET more sensitive than CT for Merkel cell carcinoma Oncology Nurse Advisor ... with traditional computed tomography (CT) imaging for evaluation of the regional lymph node basin in patients with Merkel cell carcinoma (MCC), according to research published online May 2 in the Journal of the American Academy of Dermatology. and more »

• 

  With Melanoma Rising Among Young Adults, New Treatments Could Play a Key Role - CisionWire (press release)

  Posted: May 16th, 2012, 6:31am MDT

  With Melanoma Rising Among Young Adults, New Treatments Could Play a Key Role CisionWire (press release) Currently, three Phase II clinical trials to test OncoSec's technology are underway, not only in metastatic melanoma but also in Merkel cell carcinoma and cutaneous T-cell lymphoma. There are currently few, if any, treatment options for these cancers. and more »

• 

  PET More Sensitive Than CT for Merkel Cell Carcinoma - MD News (press release)

  Posted: May 16th, 2012, 12:46am MDT

  MD News (press release)

  PET More Sensitive Than CT for Merkel Cell Carcinoma MD News (press release) Fluorine-18-fluorodeoxyglucose positron emission tomography is significantly more sensitive and equally specific compared with traditional computed tomography imaging for evaluation of the regional lymph node basin in patients with Merkel cell ... and more »

• 

  PET More Sensitive Than CT for Merkel Cell Carcinoma - Doctors Lounge

  Posted: May 15th, 2012, 9:03am MDT

  PET More Sensitive Than CT for Merkel Cell Carcinoma Doctors Lounge Fluorine-18-fluorodeoxyglucose positron emission tomography is significantly more sensitive and equally specific compared with traditional computed tomography imaging for evaluation of the regional lymph node basin in patients with Merkel cell ... and more »

• 

  Skin Cancer Awareness: With Melanoma Rising Among Young Adults, New Treatments ... - Newswise (press release)

  Posted: May 15th, 2012, 5:43am MDT

  Skin Cancer Awareness: With Melanoma Rising Among Young Adults, New Treatments ... Newswise (press release) Currently, three Phase II clinical trials to test OncoSec's technology are underway, not only in metastatic melanoma but also in Merkel cell carcinoma and cutaneous T-cell lymphoma. There are currently few, if any, treatment options for these cancers. and more »

• 

  Genomics IDs a molecular-based treatment for viral skin cancer - ScienceBlog.com (blog)

  Posted: May 15th, 2012, 5:22am MDT

  Genomics IDs a molecular-based treatment for viral skin cancer ScienceBlog.com (blog) Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Viral skin cancer treatment targets protein - Futurity: Research News

  Posted: May 14th, 2012, 8:18am MDT

  Viral skin cancer treatment targets protein Futurity: Research News The researchers “knocked out” a key viral protein called T antigen and found that Merkel cell polyomavirus (MCV) directly elevates a cellular protein called survivin, a protein that triggers tumor growth. (Credit: "virus cell" image via Shutterstock) ... and more »

• 

  Pitt team makes Quick progress against skin cancer - Pittsburgh Post Gazette

  Posted: May 11th, 2012, 8:16pm MDT

  Pitt team makes progress against skin cancer Pittsburgh Post Gazette By David Templeton / Pittsburgh Post-Gazette Merkel cell carcinoma wasn't even identified as a separate skin cancer until 30 years ago. As recent as four years ago, no one knew what caused it or how to treat it. But, in a quick succession of ... and more »

• 

  Genomics Used to Identify a Molecular-Based Treatment for a Viral Skin Cancer - Science Daily (press release)

  Posted: May 9th, 2012, 6:57pm MDT

  Genomics Used to Identify a Molecular-Based Treatment for a Viral Skin Cancer Science Daily (press release) Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Pitt/UPCI Team Uses Genomics to Identify a Molecular-based Treatment for a ... - HealthCanal.com

  Posted: May 9th, 2012, 1:09pm MDT

  Pitt/UPCI Team Uses Genomics to Identify a Molecular-based Treatment for a ... HealthCanal.com Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Pitt team uses genomics to identify a molecular-based treatment for a viral ... - Science Codex

  Posted: May 9th, 2012, 11:09am MDT

  Pitt team uses genomics to identify a molecular-based treatment for a viral ... Science Codex Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Pitt team uses genomics to identify a molecular-based treatment for a viral ... - EurekAlert (press release)

  Posted: May 9th, 2012, 10:20am MDT

  Pitt team uses genomics to identify a molecular-based treatment for a viral ... EurekAlert (press release) Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Researchers use genomics to identify a molecular-based treatment for a viral ... - Medical Xpress

  Posted: May 9th, 2012, 10:10am MDT

  Researchers use genomics to identify a molecular-based treatment for a viral ... Medical Xpress Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily diagnosed at one time, and it still has a very poor prognosis, said Patrick S. Moore, MD, MPH, and Yuan Chang, MD, ... and more »

• 

  Pitt Scientists Find Promising Treatment for Rare Skin Cancer - Essential Public Radio

  Posted: May 9th, 2012, 10:02am MDT

  Essential Public Radio

  Pitt Scientists Find Promising Treatment for Rare Skin Cancer Essential Public Radio A research team at the University of Pittsburgh has discovered a possible treatment for Merkel cell carcinoma (MCC), just four years after determing the cause of the rare skin cancer. Merkel cell polyomavirus, the agent that causes Merkel cell ... and more »

• 

  ABOUT TOWN: Stoughton Cancer Survivor to Take Part in "Celebration of Life ... - Patch.com

  Posted: May 4th, 2012, 9:22am MDT

  ABOUT TOWN: Stoughton Cancer Survivor to Take Part in "Celebration of Life ... Patch.com Mark fought for his life against the rare and deadly Merkel Cell Carcinoma. Surgery, regular chemotherapy and radiation couldn't halt the cancer, and it threatened his leg and his life. An experimental five hour procedure, called Isolated Limb Infusion ...

• 

  Benefit Set for Family of Longtime BASF Employee - Patch.com

  Posted: April 18th, 2012, 2:34pm MDT

  Benefit Set for Family of Longtime BASF Employee Patch.com The Wyandotte man retired a few months back to deal with his health after being diagnosed with a rare and aggressive cancer, Merkel Cell Carcinoma. After months of conventional treatment with little success, he opted to try alternative chemotherapy ...

• 

  Why Cancer Doesn't Always Suck - Huffington Post

  Posted: April 13th, 2012, 1:06pm MDT

  Why Cancer Doesn't Always Suck Huffington Post In many ways, cancer does suck. I know. I received that dreaded phone call on my birthday, of all days, and that day sucked. My diagnosis, Merkel Cell Carcinoma, not only destroyed the left side of my face but forced me to endure seven surgeries and a ...

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Healthcare Global (press release)

  Posted: April 11th, 2012, 2:38pm MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Healthcare Global (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Manufacturing Digital (press release)

  Posted: April 11th, 2012, 2:24pm MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Manufacturing Digital (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Business Review India (press release)

  Posted: April 11th, 2012, 1:37pm MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Business Review India (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - African Business Review (press release)

  Posted: April 11th, 2012, 1:31pm MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... African Business Review (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Business Review Europe (press release)

  Posted: April 11th, 2012, 1:20pm MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Business Review Europe (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Business Review Australia (press release)

  Posted: April 11th, 2012, 11:58am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Business Review Australia (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Business Review USA (press release)

  Posted: April 11th, 2012, 10:04am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Business Review USA (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Business Review Canada (press release)

  Posted: April 11th, 2012, 9:37am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Business Review Canada (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Medical highlights 2 articles in press - Proactive Investors USA & Canada

  Posted: April 10th, 2012, 11:34am MDT

  Proactive Investors USA & Canada

  OncoSec Medical highlights 2 articles in press Proactive Investors USA & Canada The story, titled “OncoSec Inches Ahead on Skin Cancer Zapping Technology”, highlights the company's ElectroImmunotherapy program to treat Merkel cell carcinoma, a rare type of skin cancer. OncoSec Medical offers biomedical services and also focuses on ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - Sacramento Bee

  Posted: April 10th, 2012, 5:29am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... Sacramento Bee ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  Lillian Marie Mueller - WISC Madison

  Posted: April 10th, 2012, 5:28am MDT

  WISC Madison

  Lillian Marie Mueller WISC Madison Lillian Marie Mueller, age 82, passed away on April 7, 2012 from Merkel cell carcinoma. She was born May 7, 1929 in Troy Township, Sauk County, WI, a daughter of Benjamin and Gladys (Callaway) Fuchs. Lillian attended Harrisburg School, graduated from ...

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - SYS-CON Media (press release)

  Posted: April 10th, 2012, 2:31am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... SYS-CON Media (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... - DigitalJournal.com (press release)

  Posted: April 10th, 2012, 2:02am MDT

  OncoSec Executive Team Contributes to Manufacturing Chemist and Company ... DigitalJournal.com (press release) ... titled "OncoSec Inches Ahead on Skin Cancer Zapping Technology" discusses OncoSec's development plan, highlighting the company's OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell ... and more »

• 

  ImmunoGen announces Phase II lung cancer trial, T-DM1 showing promise - Proactive Investors USA & Canada

  Posted: March 30th, 2012, 9:52am MDT

  Proactive Investors USA & Canada

  ImmunoGen announces Phase II lung cancer trial, T-DM1 showing promise Proactive Investors USA & Canada ImmunoGen's IMGN901 was developed to kill CD56 cancer cells which, aside from SCLC, also include multiple myeloma and Merkel cell carcinoma. The company said the drug has demonstrated "encouraging initial activity in these cancers as well as in SCLC in ... and more »

• 

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... - Genetic Engineering News (press release)

  Posted: March 30th, 2012, 5:48am MDT

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... Genetic Engineering News (press release) In addition to SCLC, other CD56-expressing cancers include multiple myeloma and Merkel cell carcinoma. IMGN901 has demonstrated encouraging initial activity in these cancers as well as in SCLC in early-stage clinical testing, and also has orphan drug ... and more »

• 

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... - Business Wire (press release)

  Posted: March 30th, 2012, 5:33am MDT

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... Business Wire (press release) NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned interim analysis to enable early decisions on next steps to advancement. WALTHAM, Mass. and more »

• 

  ImmunoGen begins small-cell lung cancer treatment trial - Mass High Tech

  Posted: March 30th, 2012, 4:48am MDT

  ImmunoGen begins small-cell lung cancer treatment trial Mass High Tech Immunogen's drug candidate was developed to kill CD56 cancer cells which aside from SCLC also include multiple myeloma and Merkel cell carcinoma. The product has been granted orphan drug designation for SCLC in the US and Europe, according to the ... and more »

• 

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... - PharmaLive (press release) (subscription)

  Posted: March 30th, 2012, 4:10am MDT

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... PharmaLive (press release) (subscription) NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned interim analysis to enable early decisions on next steps to advancement. WALTHAM, Mass. and more »

• 

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... - PharmiWeb.com (press release)

  Posted: March 30th, 2012, 3:09am MDT

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... PharmiWeb.com (press release) In addition to SCLC, other CD56-expressing cancers include multiple myeloma and Merkel cell carcinoma. IMGN901 has demonstrated encouraging initial activity in these cancers as well as in SCLC in early-stage clinical testing, and also has orphan drug ... and more »

• 

  IMMUNOGEN, INC. : Announces Initiation of Phase II Evaluation of Its IMGN901 ... - 4-traders

  Posted: March 30th, 2012, 2:07am MDT

  IMMUNOGEN, INC. : Announces Initiation of Phase II Evaluation of Its IMGN901 ... 4-traders NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned interim analysis to enable early decisions on next steps to advancement. ImmunoGen, Inc. (Nasdaq: IMGN) ... and more »

• 

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... - MarketWatch (press release)

  Posted: March 30th, 2012, 2:01am MDT

  ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 ... MarketWatch (press release) In addition to SCLC, other CD56-expressing cancers include multiple myeloma and Merkel cell carcinoma. IMGN901 has demonstrated encouraging initial activity in these cancers as well as in SCLC in early-stage clinical testing, and also has orphan drug ... and more »

• 

  OncoSec announces $7.75 mln public offering with institutional investors - Proactive Investors USA & Canada

  Posted: March 26th, 2012, 5:31am MDT

  Proactive Investors USA & Canada

  OncoSec announces $7.75 mln public offering with institutional investors Proactive Investors USA & Canada The goal was to launch three phase 2 based ElectroImmunotherapy trials for rare skin cancer indications, two of which have already been started. Dhillon says these two trials, for metastatic melanoma and merkel cell carcinoma, are now open for ... and more »

TOP Gregarius 0.6.1 Website: Rare-Cancer.org Last Update: Fri 25 May 2012 11:00:47 PM MDT